Ramirez Sophia, Yang Ryan, Habibovic Muhammed, Kennedy Samantha, Bennett Jonathan P, Shepherd John A, Thomas Diana M, Heymsfield Steven B
Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA.
Department of Epidemiology, University of Hawai'i Cancer Center, Honolulu, HI, USA.
Int J Obes (Lond). 2025 Jul 14. doi: 10.1038/s41366-025-01842-1.
Body weight and health-outcome results of highly effective new GLP-1R agonist medicine trials are usually presented in scientific reports in the form of standard graphs and tables. These representations are not easily translated to what the average participant looked like or their health risks at the outset of the study and how improvements in adiposity and clinical measures changed with treatment. Two recently developed methods for visually presenting complex weight and health-risk information that encapsulate substantial amounts of clinical trial observations were recently developed that can potentially supplement and give new insights into conventional GLP-1R agonist scientific reports. The current study aim was to put these visual presentations into a demonstration format to explore if and to what extent they convey new or useful information beyond traditional graphical and tabular approaches.
The first developed approach was the capability of generating, with manifold regression, humanoid avatars with accurate anthropometric dimensions. The second developed approach, body roundness index (BRI), associates a person's shape phenotype with high-risk adiposity components and multiple health outcomes; BRI can be displayed in a visual format. These two approaches were applied to produce visual representations of body size and shape in Surmount 1 average male and female participants (maximal-tolerated dose group) at baseline and after 72-weeks of tirzepatide treatment.
Developed images revealed clear excess adiposity and high health-risk (BRI) at baseline with marked improvements, although not to within the healthy BMI (<25 kg/m) and BRI ranges at 72 weeks, observations not evident in the published report. Avatar analyses revealed sexual dimorphism in regional shape (volume) changes with weight loss.
Visual presentation of new weight loss medicine trial results can supplement standard published reports by condensing substantial amounts of complex technical information in an easily understood format that can potentially yield new study insights.
高效新型胰高血糖素样肽-1受体(GLP-1R)激动剂药物试验的体重和健康结果通常以标准图表的形式呈现在科学报告中。这些呈现方式不易转化为研究开始时普通参与者的外貌或健康风险,以及肥胖和临床指标的改善如何随治疗而变化。最近开发了两种直观呈现复杂体重和健康风险信息的方法,这些方法涵盖了大量临床试验观察结果,有可能补充传统GLP-1R激动剂科学报告并提供新的见解。本研究的目的是将这些可视化呈现转化为演示形式,以探索它们是否以及在多大程度上能传达超越传统图表方法的新的或有用的信息。
第一种开发的方法是通过多元回归生成具有准确人体测量尺寸的类人化身的能力。第二种开发的方法是身体圆润度指数(BRI),它将人的形状表型与高风险肥胖成分和多种健康结果相关联;BRI可以以可视化形式显示。将这两种方法应用于生成司美格鲁肽治疗72周基线和治疗后Surmount 1试验中平均男性和女性参与者(最大耐受剂量组)的身体大小和形状的可视化表示。
所生成的图像显示,基线时明显存在过度肥胖和高健康风险(BRI),尽管在72周时未改善到健康体重指数(BMI<25kg/m)和BRI范围内,但这些观察结果在已发表的报告中并不明显。化身分析揭示了体重减轻时区域形状(体积)变化的性别差异。
新的减肥药物试验结果的可视化呈现可以通过以易于理解的格式浓缩大量复杂的技术信息来补充标准的已发表报告,这可能会产生新的研究见解。